186 related articles for article (PubMed ID: 10942065)
1. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
Hildebrandt G; Holler E; Woenkhaus M; Quarch G; Reichle A; Schalke B; Andreesen R
Ann Oncol; 2000 Jun; 11(6):743-7. PubMed ID: 10942065
[TBL] [Abstract][Full Text] [Related]
2. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
4. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
5. [Acute vincristine neurotoxicity in a non-Hodgkin's lymphoma patient with Charcot-Marie-Tooth disease].
Uno S; Katayama K; Dobashi N; Hirano A; Ogihara A; Yamazaki H; Usui N; Kobayashi T; Inoue K; Kuraishi Y
Rinsho Ketsueki; 1999 May; 40(5):414-9. PubMed ID: 10390891
[TBL] [Abstract][Full Text] [Related]
6. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K
Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085
[TBL] [Abstract][Full Text] [Related]
7. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis.
Jacobson JO; Grossbard M; Shulman LN; Neuberg D
Clin Lymphoma; 2000 Dec; 1(3):211-7; discussion 218. PubMed ID: 11707832
[TBL] [Abstract][Full Text] [Related]
8. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
9. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
11. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
[TBL] [Abstract][Full Text] [Related]
12. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
Yuan ZY; Xu RH; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
[TBL] [Abstract][Full Text] [Related]
13. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
14. Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.
Yalin SF; Trabulus S; Yalin AS; Yalin GY; Ongoren S; Altiparmak MR
Int J Clin Pharm; 2013 Jun; 35(3):306-8. PubMed ID: 23338712
[TBL] [Abstract][Full Text] [Related]
15. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198
[TBL] [Abstract][Full Text] [Related]
16. Necrotizing leukoencephalopathy following CHOP chemotherapy.
Blaes AH; Santa-Cruz KS; Lee CK; Hui SK; Peterson BA
Leuk Res; 2008 Oct; 32(10):1611-4. PubMed ID: 18378307
[TBL] [Abstract][Full Text] [Related]
17. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Chauvenet AR; Shashi V; Selsky C; Morgan E; Kurtzberg J; Bell B;
J Pediatr Hematol Oncol; 2003 Apr; 25(4):316-20. PubMed ID: 12679647
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Wilder DD; Ogden JL; Jain VK
Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
[TBL] [Abstract][Full Text] [Related]
20. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma.
DeAngelis LM; Gnecco C; Taylor L; Warrell RP
Cancer; 1991 May; 67(9):2241-6. PubMed ID: 1707337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
